Italia markets open in 3 hours 17 minutes

Alaunos Therapeutics, Inc. (TCRT)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,2900+0,0300 (+2,38%)
Alla chiusura: 04:00PM EDT
1,3500 +0,06 (+4,65%)
Dopo ore: 07:26PM EDT

Alaunos Therapeutics, Inc.

2617 Bissonnet Street
Suite 225
Houston, TX 77005
United States
346 355 4099
https://www.alaunos.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1

Descrizione

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Governance aziendale

L'ISS Governance QualityScore di Alaunos Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.